Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ciliogenesis-associated TTC17-interacting protein (CATIP, gene symbol C2orf62) is a protein involved in the formation of primary cilia on cells by regulating actin filament dynamics and ciliogenesis[1][3][9]. It plays a critical role in the organization of the actin cytoskeleton, essential for cilium assembly and maintenance of sperm structure[3][5][7][9]. Pathogenic mutations in CATIP are linked to male infertility syndromes, particularly those involving abnormal sperm morphology and motility, such as oligoteratoasthenozoospermia (OTA) and spermatogenic failure 54, due to disrupted actin organization in sperm tails[1][5][9]. This protein does not directly fall into canonical categories such as receptor, enzyme, transporter, or transcription factor; instead, it is best classified as an intracellular structural/regulatory protein[9]. No known drugs, clinical biomarkers, or safety issues are currently associated with CATIP, and it is primarily of interest in rare genetic infertility disorders rather than as a therapeutic target[1][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ciliogenesis-associated TTC17-interacting protein (CATIP).